An alternative Indian model?

This paper utilizes the dualistic model of development to analyze the development of three regions: Northeast Asia, China, and India. There are many similarities between the development processes experienced by the first two regions. They involved rapid agricultural growth as a foundation for the growth of labor-intensive manufacturing. However, India's growth process seems to have skipped over the stage of labor-intensive manufacturing growth. Switching to a more labor-intensive growth process is often seen to be dependent on reform of India's labor laws. This paper argues that such reform will not work. The labor intensity of the growth process is dependent on rapid growth in agriculture. Without this, structural change will slow and inequality worsen. The latter will likely result in a deterioration of state effectiveness.     

Updated trends in US brand-name and generic drug competition

Objective: To provide updated evidence on US trends in: market exclusivity periods (MEPs, time between brand-name drug launch and first generic competitors) for new molecular entities (NMEs); likelihood, timing and number of Hatch-Waxman Act Paragraph IV patent challenges; and generic drug penetration.

Methods: This study used IMS Health National Sales Perspectives^TM US data to calculate MEPs for the 288 NMEs experiencing initial generic entry between January 1995 and December 2014, the number of generic competitors for 12 months afterward (by level of annual sales prior to generic entry), and generic penetration rates. The likelihood, timing and number of Paragraph IV challengers were calculated using data from Abbreviated New Drug Approval (ANDA) letters, the FDA website, public information searches, and ParagraphFour.com.

Results: For drugs experiencing initial generic entry in 2013–2014, the MEP was 12.5 years for drugs with sales greater than $250 million (in 2008 dollars) in the year prior to generic entry ($250 million?+?NMEs), 13.6 years overall. After generic entry, brands rapidly lost sales, with their average unit share being 7% at 1 year for $250 million?+?NMEs, 12% overall. Ninety-four percent of $250 million?+?NMEs experiencing initial generic entry in 2013–2014 had faced at least one Paragraph IV challenge, an average of 5.2 years after brand launch (76% and 5.9 years for all NMEs). NMEs faced an average of 5.1 and 6.2 Paragraph IV challenges per NME, for all and $250 million?+?NMEs, respectively.

Limitations: Analyses, including Paragraph IV calculations, were restricted to NMEs where generic entry had occurred.

Conclusion: The average 2013–2014 MEP of 12.5 years for $250 million?+?NMEs, 13.6 overall remains consistent with prior research. MEPs are lower, and Paragraph IV challenges are more frequent and occur earlier for $250 million?+?drugs. Generic share erosion is also greater, and continues to intensify for both NME types.     

Does the use of professional legal assistance bring measurable benefits?

In this paper, the first attempt to quantify measurable effects of using legal advisory services is made with the use of a random sample and advanced econometric methods (robust MM-estimator). The estimates of parameters of an extended Mincer equation indicate that the appearance of legal problems results in lower earnings per person in a household and the choice of an active reaction to this legal problem results in a substantial reduction of losses.     

An Exchange Rate Model with Market Pressures and a Contagion Effect

The model we propose includes variables accounting for the behavioral aspects of decision-making in the currency markets, namely the contagion effect between countries in the same region. It combines the classical purchasing power parity (PPP) and uncovered interest rate parity (UIP) hypotheses with the effects of risk aversion in financial markets and of currency market pressures.

The results based on the Polish data confirm that the currency market instabilities arise not only from fundamental factors such as economic activity and the country’s balance of payments, but also from the contagion effect brought about by investors’ tendency to view Poland and its neighbors, the Czech Republic and Hungary, as one group.     

Female customers' expectation of the service offering and their perception of the service quality in an emerging clothing market

Worldwide, clothing retailers that offer similar merchandise and even the same brands are flanked almost next to one another in shopping centres. Clothing retail therefore appears to be poorly differentiated, and it is not always clear why consumers prefer to patronize one store and avoid another. This study explored female consumers' expectations of the service offering and their perception of the service quality of prominent clothing retail channels in Tshwane, a major urban area in South Africa. The survey involved 243 females that were 20 years of age or older. They completed a structured questionnaire that investigated their (1) expectations of customer service in terms of tangible evidence of the service offering; and (2) perception of service quality using two different instruments by means of a direct measurement approach. Explorative factor analysis was used to reduce the data in terms of relevant dimensions of the respective measuring instruments and to determine the significance of the various dimensions of customer service and service quality in the context of this research. Contrary to what the literature proposes about consumers in an emerging economy, findings of this study suggest that females' expectations of the service offering of clothing retail stores were high. Their expectations were cognitively structured in terms of three elements of customer service, namely (1) physical facilities and product presentation; (2) personnel; and (3) store image and processes. Their perception of service quality revealed an opportunity to augment the service quality through attention to activities that are associated with personnel and the so-called supportiveness dimensions of their service offering. Findings coincided with a prior investigation of Terblanche and Boshoff, although a re-labelling of one dimension of their instrument is proposed to prevent confusion. Recommendations to augment the service quality of clothing retailers are made in terms of tangible evidence of the service offering.     

The relative efficiency of slave agriculture: a reply

Professors Hofler and Folland have written a very interesting paper, which brings out several interesting ideas and is a contribution to the literature. They argue that their results contradict those of our original paper concerning the relative efficiency of small versus large slave farms. Specifically they find that large slave farms are relatively more efficient. However, they have missed that main point of the original paper which was to compare the relative efficiency of slave and non-slave farms. On this issue, the Holfer and Folland comment provides no additional insight. Thus their paper, while interesting, is not a comment on our original work.     

The determinants of pharmaceutical research and development expenditures

Since the late 1970s, pharmaceutical R&D has grown at a rapid rate relative to sales and other variables. In this paper, we examine the determinants of pharmaceutical R&D using a pooled data sample of 11 major drug firms over the period 1974 to 1994. We find that expected returns and cash flows are important explanatory variables of firm research intensities during this period. This is consistent with our results for an earlier sample period characterized by very different growth patterns on R&D.     

R&D Costs,Innovative Output and Firm Size in the Pharmaceutical Industry

This study examines the relationships between firm size, R&D costs and output in the pharmaceutical industry. Project–level data from a survey of 12 US–owned pharmaceutical firms on drug development costs, development phase lengths and failure rates are used to determine estimates of the R&D cost of new drug development by firm size. Firms in the sample are grouped into three size categories, according to their pharmaceutical sales at the beginning of the study period. The R&D cost per new drug approved in the US is shown to decrease with firm size, while sales per new drug approved are shown to increase markedly with firm size. Sales distributions are highly skewed and suggest that firms need to search for blockbuster drugs with above–average returns. The results are consistent with substantial economies of scale in pharmaceutical R&D, particularly at the discovery and preclinical development phases.     

Public policy and innovation: The case of pharmaceuticals

The pharmaceutical industry has been subject in recent years to an expanding set of regulatory constraints and related policy actions adversely affecting its level of innovation. The experiences of this industry provides some important insights for recent national policy discussions on declining innovation in the U.S. and the need for economic “revitalization”. The first section of the paper considers the societal benefits resulting from new drug therapies and other kinds of industrial innovation. An analysis of the basic characteristics of the R and D investment decision is then undertaken along with recent trends in various determinant factors. The last half of the paper evaluates the effects of government regulatory, patent, and reimbursement policies on R and D incentives and the level of pharmaceutical innovation. The paper concludes with several recommendations for policy changes to improve the incentives for industrial innovation in this and related high technology industries.